Focused On-demand Library for Carnitine O-palmitoyltransferase 1, brain isoform

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8TCG5

UPID:

CPT1C_HUMAN

Alternative names:

CPT IC; Carnitine O-palmitoyltransferase I, brain isoform; Carnitine palmitoyltransferase 1C

Alternative UPACC:

Q8TCG5; A8K0Z8; Q5K6N5; Q8N6Q9; Q8NDS6; Q8TE84

Background:

Carnitine O-palmitoyltransferase 1, brain isoform (CPT IC), also known as Carnitine palmitoyltransferase 1C, plays a crucial role in the lipid metabolic process. This protein, encoded by the gene with the accession number Q8TCG5, is vital for the proper functioning of cellular energy metabolism, particularly in the brain.

Therapeutic significance:

Spastic paraplegia 73, an autosomal dominant neurodegenerative disorder, is linked to variants affecting the gene encoding CPT IC. This connection highlights the protein's potential as a target for therapeutic intervention, aiming to alleviate the progressive weakness and spasticity associated with the disease.